Publications by authors named "Mark Turco"

Claim this Profile
O
Ocean State Labs Opening to Accelerate a New Era of Life Science Innovation.
Mark A Turco, Lilia Kirtley Holt, Hailey Bathurst

R I Med J (2013)· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Catheter Device Using Renal Artery Protection to Reduce Contrast-Associated Acute Kidney Injury.
Shmuel Chen, Mark Turco, Mark Reisman, Aloke V Finn

Cardiovasc Revasc Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pressure-Controlled Intermittent Coronary Sinus Occlusion: A Novel Approach to Improve Microvascular Flow and Reduce Infarct Size in STEMI.
C Michael Gibson, Issameddine Ajmi, Cajetan L von Koenig, Mark A Turco, Gregg W Stone

Cardiovasc Revasc Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study.
Armeen Mahvash, Steven Chartier, Mark Turco, Paula Habib, Steven Griffith

BMC Gastroenterol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiographic classification of patterns of restenosis following femoropopliteal artery intervention: A proposed scoring system.
Lawrence A Garcia, Krishna J Rocha-Singh, Prakash Krishnan, Thomas Zeller, Gunnar Tepe, Mark A Turco

Catheter Cardiovasc Interv· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies.
Nobuaki Kobayashi, Akiko Maehara, Dominic Allocco, Bernard Witzenbichler, Stephen G Ellis, Mark A Turco

Coron Artery Dis· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A provisional strategy for treating true bifurcation lesions employing a scoring balloon for the side branch: final results of the AGILITY trial.
Giora Weisz, D Christopher Metzger, Henry A Liberman, Charles D O'Shaughnessy, John S Douglas, Mark A Turco

Catheter Cardiovasc Interv· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Percutaneous coronary intervention with second-generation paclitaxel-eluting stents versus everolimus-eluting stents in United States contemporary practice (REWARDS TLX Trial).
Ron Waksman, Magdi Ghali, Randy Goodroe, Thomas Ryan, Mark Turco

Am J Cardiol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic modeling of new stent platforms to evaluate cost effectiveness: analysis of the TAXUS Liberté versus TAXUS express stents.
Mark A Turco, Anuraag R Kansal, Sean Stern, Stacey L Amorosi, Paul L Underwood

J Interv Cardiol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of drug-eluting stents on distal vessels.
Kohei Wakabayashi, Gary S Mintz, Neil J Weissman, Gregg W Stone, Stephen G Ellis, Mark A Turco

Circ Cardiovasc Interv· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents.
Neil J Weissman, Mark A Turco, John A Ormiston, Tift Mann, Louis A Cannon

Cardiovasc Revasc Med· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefit of the TAXUS Liberté stent in small vessels and long lesions. TAXUS ATLAS program.
John A Ormiston, Mark A Turco, Jack J Hall, Louis A Cannon, Steven J Yakubov

Circ J· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Propensity-matched patient-level comparison of the TAXUS Liberté and TAXUS element (ION) paclitaxel-eluting stents.
Dean J Kereiakes, Louis A Cannon, John A Ormiston, Mark A Turco, Tift Mann

Am J Cardiol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Integrity bare-metal stent made by continuous sinusoid technology.
Mark A Turco

Expert Rev Med Devices· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
David E Kandzari, Laura Mauri, Jeffrey J Popma, Mark A Turco, Paul A Gurbel

JACC Cardiovasc Interv· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality and appropriateness of care: the response to allegations and actions needed by the cardiovascular professional.
Ralph G Brindis, Samuel D Goldberg, Mark A Turco, Larry S Dean

Catheter Cardiovasc Interv· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
President's page: Quality and appropriateness of care: the response to allegations and actions needed by the cardiovascular professional.
Ralph Brindis, Samuel D Goldberg, Mark A Turco, Larry S Dean

J Am Coll Cardiol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.
Ghada W Mikhail, Robert T Gerber, David A Cox, Stephen G Ellis, John M Lasala, Mark A Turco

JACC Cardiovasc Interv· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
Todd C Villines, Eric J Stanek, Patrick J Devine, Mark Turco, Michael Miller

J Am Coll Cardiol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies.
Daniel H Steinberg, Gary S Mintz, Lazar Mandinov, Alan Yu, Steven G Ellis, Mark A Turco

JACC Cardiovasc Interv· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary incidence and predictors of major adverse cardiac events after saphenous vein graft intervention with embolic protection (an AMEthyst trial substudy).
Srihari S Naidu, Mark A Turco, Laura Mauri, Alanna Coolong, Jeffrey J Popma

Am J Cardiol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions.
Takahiro Uchida, Jeffrey Popma, Gregg W Stone, Stephen G Ellis, Mark A Turco

JACC Cardiovasc Interv· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
Stephen G Ellis, Gregg W Stone, David A Cox, James Hermiller, Charles O'Shaughnessy, Mark Turco

JACC Cardiovasc Interv· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
Hiroshi Doi, Akiko Maehara, Gary S Mintz, Alan Yu, Hong Wang, Mark A Turco

JACC Cardiovasc Interv· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term paclitaxel-eluting stent outcomes in elderly patients.
Daniel E Forman, David A Cox, Stephen G Ellis, John M Lasala, John A Ormiston, Mark A Turco

Circ Cardiovasc Interv· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis